Answer
The safety and efficacy of Blincyto (blinatumomab) have not been studied in patients with severe renal impairment or severe hepatic impairment.
Sources for this answer
- BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusionAmgen Ltd · emc · SmPC §4.2 Posology and method of administration · Version 25Document updated
Sources checked